Imagine A World Without HIV

AddimmuneTM envisions a world without HIV. By harnessing the power of gene therapy, we believe we can achieve what was once thought impossible: a cure.

addy-ten-x

Addimmune to Go Public with 10X Capital Venture Acquisition Corp. III

Gene Therapy is the Future of Medicine

Our clinical milestones progress gives us confidence that we are on track for a potential HIV Cure.  Using our unique technology we can actually put a little bit of DNA in each cell that reprograms it the way we want it to.

youtube-video-thumbnail

Watch How
AddimmuneTM Pursues a Cure
for HIV with Gene Therapy

Milestones Reached
HIV Cure Countdown

HIV Cure Countdown

This HIV Cure Countdown outlines the critical milestones accomplished so far. We still have a few more to go, so follow along with us as we pursue a gene therapy cure for HIV.

Addimmune Clinical Trial Progress

  • FEB - 2019

    NIAID signs collaborative research agreement for HIV/AIDS cure strategy

  • MAY - 2019

    HIV program granted a second patent for its unique molecule, methods, and cell process

  • APR - 2020

    FDA granted Type-A meeting for HIV cure IND

  • AUG - 2020

    FDA grants IND approval

  • OCT - 2020

    HIV cure program Phase 1 begins (first patient enrolled)

  • NOV - 2020

    HIV cure program second patient enrolled and first patient product complete

  • FEB - 2019

    NIAID signs collaborative research agreement for HIV/AIDS cure strategy

  • MAY - 2019

    HIV program granted a second patent for its unique molecule, methods, and cell process

  • APR - 2020

    FDA granted Type-A meeting for HIV cure IND

  • AUG - 2020

    FDA grants IND approval

  • OCT - 2020

    HIV cure program Phase 1 begins (first patient enrolled)

  • NOV - 2020

    HIV cure program second patient enrolled and first patient product complete

Clinical Trial Progress

  • APR - 2021

    First product cleared for infusion

  • MAY - 2021

    First patient infusion; no adverse events

  • JUL - 2021

    HIV cure program initial efficacy markers

  • NOV - 2021

    First safety report by DSMB; no safety concerns

  • AUG - 2022

    Analytical Treatment Interruption (ATI)

  • NOV - 2022

    Phase 1 Data was Published in Frontiers in Medicine Journal

Addimmune Latest News

Visit our blog section to keep up to date on the latest Addimmune news

Addimmune Launched with the Sole Purpose to Cure HIV

AGT Outside-footer

Our Location

9713 Key West Ave 5th Floor,
Rockville, MD 20850,
United States

(301) 337-2100

Discover How Gene Therapy Has The Potential to Cure HIV.

Follow our journey and find out how our AddimmuneTM is making history in the fight against HIV. Subscribe to our newsletter today.

Subscribe Here!

Addimmune

Scroll to Top